(Q34579911)

3 August 2017

title

52-week efficacy and safety of telbivudine with conditional tenofovir intensification at week 24 in HBeAg-positive chronic hepatitis B (English)

1 reference

3 August 2017

1 reference

1 reference

1 reference

11

Stefan Zeuzem

1 reference

Wattana Sukeepaisarnjaroen

3 August 2017

4

Wattana Sukeepaisarnjaroen

0 references

Piyawat Komolmit

Piyawat Komolmit

2

0 references

Tawesak Tanwandee

3

Tawesak Tanwandee

1 reference

3 August 2017

1

Teerha Piratvisuth

1 reference

Wattana Sukeepaisarnjaroen

3 August 2017

4

Wattana Sukeepaisarnjaroen

1 reference

3 August 2017

Henry L Y Chan

5

1 reference

3 August 2017

Mário G Pessôa

6

1 reference

3 August 2017

Eduardo Fassio

7

1 reference

3 August 2017

Suzane K Ono

8

1 reference

3 August 2017

Fernando Bessone

9

1 reference

3 August 2017

Jorge Daruich

10

1 reference

3 August 2017

Hugo Cheinquer

12

1 reference

3 August 2017

Rashidkhan Pathan

13

1 reference

3 August 2017

Yuhong Dong

14

1 reference

3 August 2017

Aldo Trylesinski

15

1 reference

3 August 2017

language of work or name

English

0 references

publication date

4 February 2013

1 reference

3 August 2017

1 reference

3 August 2017

volume

8

1 reference

3 August 2017

issue

2

1 reference

3 August 2017

page(s)

e54279

1 reference

Creative Commons Attribution 4.0 International

3 August 2017

copyright license

start time

4 February 2013

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3563589

Hepatitis B virus DNA levels and outcomes in chronic hepatitis B.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3563589

Monitoring during and after antiviral therapy for hepatitis B.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3563589

Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3563589

Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: A randomized international study of entecavir versus adefovir.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3563589

EASL Clinical Practice Guidelines: management of chronic hepatitis B.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3563589

2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3563589

Telbivudine versus lamivudine in patients with chronic hepatitis B

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3563589

Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3563589

Report of an international workshop: Roadmap for management of patients receiving oral therapy for chronic hepatitis B.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3563589

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3563589

Cross-resistance testing of next-generation nucleoside and nucleotide analogues against lamivudine-resistant HBV.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3563589

Epidemiology and natural history of hepatitis B.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3563589

Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3563589

Serum HBV DNA as a marker of efficacy during therapy for chronic HBV infection: analysis and review of the literature

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3563589

A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3563589

Prediction of creatinine clearance from serum creatinine

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3563589

Renal safety of adefovir dipivoxil in patients with chronic hepatitis B: two double-blind, randomized, placebo-controlled studies

7 July 2018

1 reference

Crossref

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0054279

Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0054279

Effect of HBV polymerase inhibitors on renal function in patients with chronic hepatitis B.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3563589

Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B.

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3563589

Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3563589

Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease.

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3563589

[The degree of HBV suppression with 24 week telbivudine- or lamivudine-treatment in hepatitis B patients predicts the efficacy of the treatment at week 52]

27 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23390496

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Hepatitis B virus infection

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23390496

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1371/JOURNAL.PONE.0054279

1 reference

3 August 2017

0 references

1 reference

3 August 2017

1 reference